Physician profile
Kay Kovac
NPI 1326159450
$790.98
in general payments reported to CMS, 2019-2025
11 companies · $49.64 in 2025
The $49.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.05 · 2020: $332 · 2021: $36.90 · 2022: $206 · 2023: $116 · 2024: $38.42 · 2025: $49.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Venclose INC. | $242.29 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $232.29 | 2022-2023 | |
| Pfizer INC. | $68.34 | 2020-2025 | |
| Lilly USA, LLC | $57.48 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $48.16 | 2020-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $37.24 | 2022-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $37.15 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.05 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2022 | |
| Astellas Pharma US INC | $14.12 | 2025 | Veozah |
| Abbott Laboratories | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Kovac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.